Related Experiment Video
Updated: Aug 6, 2026
Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
AI-Driven Discovery and BSL-4 Validation of Cross-Filovirus Ebola-Marburg Inhibitors and their Synergistic
Holli-Joi Martin1, Marcus Tullius Scotti1,2, Sankalp Jain3
1University of North Carolina (UNC), Chapel Hill, NC, 27599, USA.
Abstract:
Filovirus outbreaks caused by Ebola virus (EBOV) and Marburg virus (MARV), pose severe global health threats characterized by high rates of fatal hemorrhagic fever. While species-specific vaccines and therapeutic monoclonal antibodies are approved for Zaire ebolavirus, broadly-active therapeutics remain unavailable, leaving populations vulnerable to MARV and other pathogenic Ebola species, such as Bundibugyo (BDBV) and Sudan (SUDV) ebolaviruses. Here we report a computationally guided, infectious virus validated screening platform for the rapid discovery of broad-spectrum filovirus antivirals. By leveraging quantitative structure- activity relationship (QSAR) models, we screened 142,382 compounds in silico to prioritize 125 high-potential candidates. Subsequent dose-response and viability profiling identified 23 compounds exhibiting potent, low-micromolar pan-filovirus activity and favorable cytotoxicity profiles. Molecular docking indicates these compounds target conserved structural and functional domains-primarily the VP35 and L proteins-which may disrupt essential viral replication and immune antagonism. Furthermore, systematic combinatorial screening revealed three highly synergistic compound pairs, notably NCGC00113249-01 and NCGC00118008-01, demonstrating robust cross-species efficacy. By targeting conserved vulnerabilities across the filovirus family, this integrated in silico and in vitro pipeline provides a scalable framework to rapidly nominate and optimize synergistic therapeutic regimens against both endemic and emerging viral threats including BDBV.
Insights
Researchers developed a computational screening platform to discover broad-spectrum filovirus antivirals. This approach identified potent compounds targeting conserved viral proteins, offering new hope against Ebola virus (EBOV) and Marburg virus (MARV) threats.
Area of Science:
- Virology
- Drug Discovery
- Computational Chemistry
Background:
- Filoviruses, including Ebola virus (EBOV) and Marburg virus (MARV), cause severe hemorrhagic fevers with high fatality rates.
- Existing treatments are largely species-specific, leaving gaps in protection against diverse filovirus threats.
- Broad-spectrum antivirals are critically needed to address MARV and other Ebola species like Bundibugyo (BDBV) and Sudan (SUDV).
Purpose of the Study:
- To establish a computationally guided screening platform for rapid discovery of broad-spectrum filovirus antivirals.
- To identify and validate novel compounds with pan-filovirus activity.
- To explore synergistic combinations of antiviral compounds for enhanced efficacy.
Main Methods:
- Utilized quantitative structure-activity relationship (QSAR) models for *in silico* screening of over 142,000 compounds.
- Conducted dose-response and viability profiling to identify compounds with potent antiviral activity and low cytotoxicity.
- Employed molecular docking to predict drug targets within conserved viral protein domains.
- Performed combinatorial screening to discover synergistic compound pairs.
Main Results:
- Prioritized 125 high-potential compounds from *in silico* screening.
- Identified 23 compounds demonstrating potent, low-micromolar pan-filovirus activity and favorable safety profiles.
- Molecular docking suggested targeting of conserved VP35 and L viral proteins.
- Discovered three synergistic compound pairs, including NCGC00113249-01 and NCGC00118008-01, with cross-species efficacy.
Conclusions:
- An integrated *in silico* and *in vitro* pipeline enables rapid discovery of broad-spectrum filovirus antivirals.
- Identified compounds targeting conserved viral proteins offer a promising strategy against diverse filoviruses.
- Synergistic compound combinations present a viable approach for developing robust therapeutic regimens against filovirus threats, including BDBV.
